Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.18.

  • ImmunityBio's Asset Utilization Ratio rose 88883.48% to 0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year increase of 88883.48%. This contributed to the annual value of 0.03 for FY2024, which is 221560.9% up from last year.
  • ImmunityBio's Asset Utilization Ratio amounted to 0.18 in Q3 2025, which was up 88883.48% from 0.16 recorded in Q2 2025.
  • ImmunityBio's Asset Utilization Ratio's 5-year high stood at 0.18 during Q3 2025, with a 5-year trough of 0.0 in Q1 2024.
  • Moreover, its 5-year median value for Asset Utilization Ratio was 0.0 (2021), whereas its average is 0.03.
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first tumbled by 7545.25% in 2022, then skyrocketed by 1352709.33% in 2025.
  • ImmunityBio's Asset Utilization Ratio (Quarter) stood at 0.0 in 2021, then tumbled by 75.45% to 0.0 in 2022, then soared by 97.87% to 0.0 in 2023, then surged by 2871.13% to 0.04 in 2024, then surged by 354.38% to 0.18 in 2025.
  • Its Asset Utilization Ratio stands at 0.18 for Q3 2025, versus 0.16 for Q2 2025 and 0.09 for Q1 2025.